X
Xiaotong Li
Researcher at China Pharmaceutical University
Publications - 12
Citations - 206
Xiaotong Li is an academic researcher from China Pharmaceutical University. The author has contributed to research in topics: Medicine & Chemistry. The author has an hindex of 2, co-authored 3 publications receiving 12 citations.
Papers
More filters
Journal ArticleDOI
Biological drug and drug delivery-mediated immunotherapy.
TL;DR: The potential targets for immunotherapy against the major inflammatory diseases are reviewed, the biologics and drug delivery systems involved in the immunotherapy are discussed, the approved therapy tactics are highlighted, and perspectives in this field are offered.
Journal ArticleDOI
Liposome-based delivery of biological drugs
TL;DR: The types of liposomes and their applications as carriers for biological drugs to treat various diseases are reviewed, the commercial products are emphasized, and perspectives in this field are provided.
Journal ArticleDOI
The effects of protein corona on in vivo fate of nanocarriers.
Qingqing Xiao,Makhloufi Zoulikha,Min Qiu,Chao Ti Teng,Chenshi Lin,Xiaotong Li,Marwa Ahmed Sallam,Qiaobing Xu,Wei He +8 more
TL;DR: In this paper , a molecular-level understanding of the in-vivo fate of nanocarriers is presented, emphasizing the in vivo environmental factors that control the protein corona (PC) formation.
Journal ArticleDOI
Liposome-based anchoring and core-encapsulation for combinatorial cancer therapy
TL;DR: In this paper , a co-delivery of a pro-apoptotic protein, caspase 3 (Cas 3), and cytotoxic agent, oridonin (ORD), using a method of liposome-based anchoring and core encapsulation is reported.
Journal ArticleDOI
Targeted co-delivery of daunorubicin and cytarabine based on the hyaluronic acid prodrug modified liposomes
George Frimpong Boafo,Yejiao Shi,Qingqing Xiao,Kosheli Thapar Magar,Makhloufi Zoulikha,Xuyang Xing,Chao Ti Teng,E. Brobbey,Xiaotong Li,Xiaohong Jiang,Xiaochun Wang,Yi Jia Yang,Samuel Kesse,W He +13 more
TL;DR: In this article , a targeted Daunorubicin (DNR) and cytarabine (ara-C) co-delivery system was developed by modifying the ara-C loaded liposomes with the hyaluronic acid-DNR prodrugs.